ID

32993

Description

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01432405

Lien

https://clinicaltrials.gov/show/NCT01432405

Mots-clés

Versions (1)
  1. 22/11/2018 22/11/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

22 novembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type 2 Diabetes Mellitus NCT01432405

Anglais

Eligibility Type 2 Diabetes Mellitus NCT01432405

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients must range in age from 30 to 70 years.
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
2. patients must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
Description

Able to communicate Research Personnel | Competence Legal Informed Consent

Type de données

boolean

Alias
UMLS CUI [1,1]
C2364293
UMLS CUI [1,2]
C0035173
UMLS CUI [2,1]
C0086035
UMLS CUI [2,2]
C1301860
UMLS CUI [2,3]
C0021430
3. patients may be of either sex. female patients must be non-lactating and must either be at least two years post-menopausal, or be using adequate contraceptive precautions or be surgically sterilized.
Description

Gender | Breast Feeding Absent | Postmenopausal state Duration | Gender Contraceptive methods | Female Sterilization

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2,1]
C0006147
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C0232970
UMLS CUI [3,2]
C0449238
UMLS CUI [4,1]
C0079399
UMLS CUI [4,2]
C0700589
UMLS CUI [5]
C0015787
4. patients must meet the american diabetes association criteria for diagnosis of type 2 diabetes mellitus.
Description

Diabetes Mellitus, Non-Insulin-Dependent

Type de données

boolean

Alias
UMLS CUI [1]
C0011860
5. patients must be on diet therapy alone and/or metformin treatment (stable dose) and have a fasting plasma glucose concentration between 126 and 260 mg/dl.
Description

Diet therapy | Metformin Dose Stable | Plasma fasting glucose measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0012159
UMLS CUI [2,1]
C0025598
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
UMLS CUI [3]
C0583513
6. patients must have hematocrit greater than 34%.
Description

Hematocrit level

Type de données

boolean

Alias
UMLS CUI [1]
C0518014
7. subjects whose body weight has been stable (±1 kg) over the three months prior to study will be included.
Description

Stable body weight Duration

Type de données

boolean

Alias
UMLS CUI [1,1]
C0517386
UMLS CUI [1,2]
C0449238
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1, type 1 diabetes.
Description

Diabetes Mellitus, Insulin-Dependent

Type de données

boolean

Alias
UMLS CUI [1]
C0011854
2. fasting plasma glucose greater than 260 mg/dl.
Description

Plasma fasting glucose measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0583513
3. patients must not have received a thiazolidinedione for at least 3 months prior to randomization.
Description

Thiazolidinediones

Type de données

boolean

Alias
UMLS CUI [1]
C1257987
4. patients must not be on insulin treatment or have received insulin for more than one week within the previous year prior to entry. patients should not be on sulfonylureas, sitagliptin, or exenatide treatment.
Description

Insulin regime | Insulin | Sulfonylurea | sitagliptin | exenatide

Type de données

boolean

Alias
UMLS CUI [1]
C0557978
UMLS CUI [2]
C0021641
UMLS CUI [3]
C0038766
UMLS CUI [4]
C1565750
UMLS CUI [5]
C0167117
5. patients taking systemic glucocorticoids or other medications known to affect glucose tolerance are excluded.
Description

Glucocorticoids, Systemic | Pharmaceutical Preparations Affecting Glucose tolerance

Type de données

boolean

Alias
UMLS CUI [1]
C3540777
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0392760
UMLS CUI [2,3]
C0178665
6. patients taking medications that affect gastrointestinal motility will be excluded
Description

Pharmaceutical Preparations Affecting Gastrointestinal Motility

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0017184
7. patients with a history of chf, or clinically significant cardiac, liver or kidney disease (creatinine greater than 1.8 mg/dl).
Description

Congestive heart failure | Heart Disease | Liver disease | Kidney Disease | Creatinine measurement, serum

Type de données

boolean

Alias
UMLS CUI [1]
C0018802
UMLS CUI [2]
C0018799
UMLS CUI [3]
C0023895
UMLS CUI [4]
C0022658
UMLS CUI [5]
C0201976
Retour au début de la page

Similar models

Eligibility Type 2 Diabetes Mellitus NCT01432405

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. patients must range in age from 30 to 70 years.
boolean
C0001779 (UMLS CUI [1])
Able to communicate Research Personnel | Competence Legal Informed Consent
Item
2. patients must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
boolean
C2364293 (UMLS CUI [1,1])
C0035173 (UMLS CUI [1,2])
C0086035 (UMLS CUI [2,1])
C1301860 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,3])
Gender | Breast Feeding Absent | Postmenopausal state Duration | Gender Contraceptive methods | Female Sterilization
Item
3. patients may be of either sex. female patients must be non-lactating and must either be at least two years post-menopausal, or be using adequate contraceptive precautions or be surgically sterilized.
boolean
C0079399 (UMLS CUI [1])
C0006147 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0232970 (UMLS CUI [3,1])
C0449238 (UMLS CUI [3,2])
C0079399 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0015787 (UMLS CUI [5])
Diabetes Mellitus, Non-Insulin-Dependent
Item
4. patients must meet the american diabetes association criteria for diagnosis of type 2 diabetes mellitus.
boolean
C0011860 (UMLS CUI [1])
Diet therapy | Metformin Dose Stable | Plasma fasting glucose measurement
Item
5. patients must be on diet therapy alone and/or metformin treatment (stable dose) and have a fasting plasma glucose concentration between 126 and 260 mg/dl.
boolean
C0012159 (UMLS CUI [1])
C0025598 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0583513 (UMLS CUI [3])
Hematocrit level
Item
6. patients must have hematocrit greater than 34%.
boolean
C0518014 (UMLS CUI [1])
Stable body weight Duration
Item
7. subjects whose body weight has been stable (±1 kg) over the three months prior to study will be included.
boolean
C0517386 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent
Item
1, type 1 diabetes.
boolean
C0011854 (UMLS CUI [1])
Plasma fasting glucose measurement
Item
2. fasting plasma glucose greater than 260 mg/dl.
boolean
C0583513 (UMLS CUI [1])
Thiazolidinediones
Item
3. patients must not have received a thiazolidinedione for at least 3 months prior to randomization.
boolean
C1257987 (UMLS CUI [1])
Insulin regime | Insulin | Sulfonylurea | sitagliptin | exenatide
Item
4. patients must not be on insulin treatment or have received insulin for more than one week within the previous year prior to entry. patients should not be on sulfonylureas, sitagliptin, or exenatide treatment.
boolean
C0557978 (UMLS CUI [1])
C0021641 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
C1565750 (UMLS CUI [4])
C0167117 (UMLS CUI [5])
Glucocorticoids, Systemic | Pharmaceutical Preparations Affecting Glucose tolerance
Item
5. patients taking systemic glucocorticoids or other medications known to affect glucose tolerance are excluded.
boolean
C3540777 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0178665 (UMLS CUI [2,3])
Pharmaceutical Preparations Affecting Gastrointestinal Motility
Item
6. patients taking medications that affect gastrointestinal motility will be excluded
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
Congestive heart failure | Heart Disease | Liver disease | Kidney Disease | Creatinine measurement, serum
Item
7. patients with a history of chf, or clinically significant cardiac, liver or kidney disease (creatinine greater than 1.8 mg/dl).
boolean
C0018802 (UMLS CUI [1])
C0018799 (UMLS CUI [2])
C0023895 (UMLS CUI [3])
C0022658 (UMLS CUI [4])
C0201976 (UMLS CUI [5])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial